PHASE I STUDY OF PHOTODYNAMIC THERAPY FOR SURFACE MALIGNANCIES

光动力疗法包括使用一种光激活的化合物 它定位在肿瘤中，然后激活这个 光敏复方剂用于细胞毒作用的治疗 癌症。目前的方案使用静脉给药 血卟啉衍生物的Photofrin II制备方法。 目前唯一被批准用于人类的光敏剂。 接下来是将光线投射到受影响的区域。 使用光纤将光定向到肿瘤上， 氩/泵浦染料激光器。选择性血卟啉衍生物 与某些正常组织相比，定位于肿瘤。这个 其机制目前尚不清楚，但已被证实。 在动物和患者中都有记录。选择性保留 与聚焦光传递相结合的光敏剂 受累区域允许选择性地用 对未受累的正常组织影响最小。血卟啉 派生的光动力疗法可能在临床上有用 肿瘤累及的解剖部位数。

Photodynamic therapy involves the use of a light activated compound which localizes in tumor, followed by the activation of this compound by light for cytotoxic effects for the treatment of cancer. The current protocol uses the intravenous administration of the Photofrin II preparation of the hematoporphyrin derivative. the only currently approved photosensitizer for use in humans. This is followed by the delivery of light to the affected area. Light is directed at the tumor using optical fibers coupled to a argon/pumped dye laser. Hematoporphyrin derivative selectively localizes in tumor compared to certain normal tissues. The mechanism of this is not well understood at this time, but has been documented in both animals &nd in patients. Selective retention of the photosensitizer in combination with focal light delivery to the involved area permits selective destruction of tumor with minimal effect on uninvolved normal tissue. Hematoporphyrin derivative photodynamic therapy may be clinically useful in a number of anatomic sites involved by tumor.